47.4 million for the quarter ended December 31, 2011, compared to $94.2 million for the comparable prior year period. Excluding the impact of purchase accounting and other special items in both periods, as mentioned above, as well as charges for litigation settlements, net, of $20.1 million and $112.8 million for the current and prior year periods, earnings from operations increased to $355.1 million in the current quarter from $301.4 million in the prior year quarter. This increase was driven by higher gross profit in the current year, mainly as a result of the increase in revenues and gross margins as discussed above, partially offset by increases in selling, general and administrative costs (SG&A).
Interest expense for the three months ended December 31, 2011, totaled $81.1 million, compared to $91.5 million for the comparable prior year period. Included in interest expense for the current quarter and the comparable prior year period are $13.0 million and $18.0 million, respectively, primarily related to the amortization of the discounts on our convertible debt instruments and 2018 Senior Notes, net of amortization of the premium on our 2020 Senior Notes.
Other (expense) income, net, was expense of $37.4 million for the three months ended December 31, 2011 compared to expense of $4.8 million in the comparable prior year period. Generally included in other (expense) income, net, are foreign exchange gains and losses and interest and dividend income. Additionally, included in the current period are charges associated with the termination of certain interest rate swaps totaling $13.9 million and the write-off of previously deferred financing fees of $20.1 million related to the refinancing of our senior credit facility which occurred in November 2011.
EBITDA, which is defined as net income (loss) (excluding the non-controlling interest and income from equity method investees) plus income taxes, interest expense, depreciatiPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine technology :1
. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement2
. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty3
. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection4
. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers5
. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant6
. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan7
. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®8
. Mylan to Host Investor Day on Feb. 21, 2012, in New York City9
. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam10
. Mylan Launches First Generic Version of Teveten® Tablets11
. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets